secwatch.observer — SEC 8-K summary
======================================

Issuer:     Calidi Biotherapeutics, Inc. (CLDI)
CIK:        0001855485
Form:       8-K
Filed at:   2023-10-30T23:59:59+00:00
Accession:  0001493152-23-038596
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 1.01, 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Calidi Biotherapeutics appoints Andrew Jackson as CFO effective Oct 30, 2023
----------------------------------------------------------------------------

- Base salary $430k, annual bonus up to 35% of base, 300k incentive stock options with one-year cliff and 4-year vesting.
- Severance: 6 months' base salary if terminated without cause or resigns with good reason; 12 months after change of control.
- Jackson has over 25 years corporate finance experience, raised over $300M in financings, previously CFO at Eterna Therapeutics and Ra Medical Systems.
- Led Ra Medical's IPO and established public company processes, controls, and infrastructure.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1855485/000149315223038596/0001493152-23-038596-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1855485/000149315223038596/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-038596

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer